CoChat

Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches

Open access
Roemer, T., Krysan, D. J. · 2014 · Cold Spring Harbor Perspectives in Medicine

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.

Abstract

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.

Overview

Integrity signals

Registry

Crossref · 10.1101/cshperspect.a019703

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 77 references

Cited by

See all 620

Metadata

Authors
Roemer, T., & Krysan, D. J.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University of Rochester Medicine (US)
Venue
Cold Spring Harbor Perspectives in Medicine
Published
2014-05-01
Volume
4
Issue
5
Pages
a019703-a019703
ISSN
2157-1422 (ISSN-L)
OpenAlex
W2134122507
Cited by
593
References
78
Citations by year
2026: 39 · 2025: 56 · 2024: 69 · 2023: 51 · 2022: 58 · 2021: 68 · 2020: 71 · 2019: 42 · 2018: 50 · 2017: 38 · 2016: 30 · 2015: 18 · 2014: 3
Type
posted content
Language
en
Open access
Locations
  • Cold Spring Harbor Perspectives in Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Rochester
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (R01AI097142, R01AI091422)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
antifungal drug development, invasive fungal infections, antifungal drug discovery, unmet clinical needs, immunocompromised patients
MeSH terms
Antifungal Agents, Forecasting, Humans, Mycoses, Technology, Pharmaceutical, Treatment Outcome, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.